drugset / Trial / NCT04551079

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

NCT04551079 ↗

Phase 1 Completed 19 enrolled Takeda
RandomizedCrossoverDouble-blindOther

Summary

The purpose of this study is to assess the safety and tolerability of TAK-994 and to determine the effect of TAK-994 (compared to placebo) on sleepiness, as measured by mean sleep latency on the maintenance of wakefulness Test (MWT), in an acute sleep phase delay paradigm in healthy participants.

Timeline

Start
2020-09-23
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-994 Unknown — Oral

Indications

No indication recorded.